DOCSLIB.ORG

Fluoroarenes for Use in the Medical Imaging Technique

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fluoroarenes for Use in the Medical Imaging Technique DIARYLIODONIUM SALTS AS PRECURSORS TO 18 ELECTRON-RICH [ F]FLUOROARENES FOR USE IN THE MEDICAL IMAGING TECHNIQUE – POSITRON EMISSION TOMOGRAPHY SATWINDER SINGH BHATT Submitted in fulfilment of the requirements for the degree of Doctor of Philosophy. Sir Bobby Robson Foundation PET Tracer Production Unit, School of Chemistry, Newcastle University January 2016 Contents Acknowledgements ....................................................................................... v List of Abbreviations ................................................................................... vii 1 Introduction ......................................................................................... 1 1.1 Positron Emission Tomography ................................................................. 1 1.2 Radioisotopes in PET Imaging ................................................................... 9 1.3 Fluorine in Pharmaceuticals .................................................................... 12 1.4 PET Imaging with Fluorine-18 ................................................................. 17 1.5 Cyclotron Production of Fluorine-18 ......................................................... 19 1.5.1 Radiochemical Terminology ................................................................. 21 1.5.2 Production of Electrophilic Fluorine-18 .................................................. 24 1.5.3 Production of Nucleophilic Fluorine-18 .................................................. 25 1.5.4 Radiopharmaceutical Production .......................................................... 27 1.6 Approaches to [18F]Fluorine Radiolabelling ............................................... 31 1.6.1 Electrophilic [18F]Fluorinations.............................................................. 32 1.6.2 Nucleophilic [18F]Fluorinations .............................................................. 37 1.6.2.1 Nucleophilic Aliphatic Substitutions with [18F]Fluoride ......................... 38 1.6.2.3 Nucleophilic Aromatic Substitutions with [18F]Fluoride ........................ 41 1.6.2.3 The Balz-Schiemann and Wallach Reactions ....................................... 47 1.6.2.4 Newer Strategies for Fluorine-18 Incorporation .................................. 49 1.7 Fluorine-18 Labelling with Prosthetic Groups ............................................ 59 1.7.1 Amine Reactive Prosthetic Groups ........................................................ 63 1.7.2 Thiol Reactive Prosthetic Groups .......................................................... 65 1.7.3 Click-Chemistry Approaches to Fluorine-18 Labelling ............................. 68 1.7.4 Transition-metal Catalysed Cross-coupling Prosthetic Groups ................. 70 1.7.5 Carbonyl Reactive Prosthetic groups ..................................................... 72 1.8 [18F]Fluorophenols as Prosthetic Groups .................................................. 73 2 Diaryliodonium Salts for Radiolabelling Electron-rich Aromatics ........ 79 2.1 Introduction to Hypervalent Iodine Chemistry .......................................... 79 2.2 Reactivity of Diaryliodonium Salts ............................................................ 83 2.2.1 Chemoselectivity of Diaryliodonium Salt Fluorination ............................. 85 2.2.2 Applications of Diaryliodonium Salts ..................................................... 92 2.3 Synthesis of Diaryliodonium Salts ............................................................ 93 2.4 A Strategy for 4-[18F]Fluorophenol Production .......................................... 97 i 2.5 Preparation of Aryliodobis(acetate)s ........................................................ 99 2.6 Preparation of Arylstannanes ................................................................. 105 2.7 Preparation of Diaryliodonium Salts for 4-[18F]Fluorophenol Production .... 111 2.8 [19F]Fluorination of Diaryliodonium Salts ................................................. 121 2.9 Improving Selectivity ............................................................................. 127 2.10 Chapter 2 Summary ........................................................................... 131 3 Microfluidic Radiofluorination of Diaryliodonium Salts...................... 132 3.1 Automated Radiochemistry .................................................................... 133 3.2 Radiosynthesis with the Advion NanoTek Microfluidic System ................... 138 3.3 Radiosynthesis of Protected-4-[18F]fluorophenol ...................................... 142 3.4 Chapter 3 Summary .............................................................................. 151 4 Diaryliodonium Routes to 6-[18F]Fluoro-m-tyramine ........................ 152 4.1 Diaryliodonium Salt Precursors to 6-[18F]Fluoro-m-tyramine .................... 154 4.2 [19F]Fluorination of 6-Fluoro-m-tyramine Precursors ................................ 159 4.3 [18F]Fluorination of 6-Fluoro-m-tyramine Precursors ................................ 163 4.4 Chapter 4 Summary .............................................................................. 167 5 Diaryliodonium Routes to [18F]FDOPA ............................................... 168 5.1 Introduction to [18F]FDOPA .................................................................... 168 5.2 Current Routes to [18F]FDOPA ............................................................... 172 5.3 [18F]FDOPA Diaryliodonium Salt Precursor Strategy ................................. 181 5.4 Initial Challenges in [18F]FDOPA Diaryliodonium Salt Development ........... 185 5.5 Diaryliodonium Salt Precursor to 6-[18F]Fluorodopamine .......................... 189 5.6 Redesign of the [18F]FDOPA Diaryliodonium Salt ..................................... 193 5.4 Chapter 5 Summary .............................................................................. 201 7 Conclusions and Further Work............................................................ 202 9 Experimental ....................................................................................... 204 9.1 Phenyliodobis(acetate) (132)261,412 ......................................................... 204 9.2 2-Thienyliodobis(acetate) (133)255,411 ..................................................... 205 9.3 4-Methoxyphenyliodobis(acetate) (134)255,412 .......................................... 205 9.4 2-Methoxyphenyliodobis(acetate) (135)255,412 .......................................... 206 9.5 4-Methylphenyliodobis(acetate) (136)261,412 ............................................ 206 9.6 2,4,6-Trimethylphenyliodobis(acetate) (137)261,412 ................................... 207 9.7 4-(Benzyloxy)phenyliodobis(acetate) (166)221 ......................................... 207 9.8 4-(Benzyloxy)-1-iodobenzene (140)413,414 ................................................ 208 9.9 4-(Benzyloxy)-1-bromobenzene (141)413,414 ............................................ 209 9.10 4-Iodophenyl acetate (142)415,416 ........................................................ 209 9.11 4-Bromophenyl acetate (143)415 .......................................................... 210 ii 9.12 4-(Benzyloxy)-1-fluorobenzene (157)416 ...............................................210 9.13 4-(Benzyloxy)-1-tributylstannylbenzene (146)318,319,320 ..........................211 9.14 4-(Acetoxy)-1-tributylstannylbenzene (147)318,319,320 .............................212 9.15 4-(Methoxy)-1-tributylstannylbenzene (148)318,319,320 ............................212 9.16 (3,4,5-trimethoxy)-1-tributylstannylbenzene (169)318,319,320 ...................213 9.17 (4-(Benzyloxy)phenyl)(4-methoxyphenyl)iodonium trifluoroacetate (149) ... .........................................................................................................213 9.18 (4-(Benzyloxy)phenyl)(2-thienyl)iodonium trifluoroacetate (150) ...........214 9.19 (4-(Benzyloxy)phenyl)(phenyl)iodonium trifluoroacetate (151) ..............215 9.20 (4-(Acetoxy)phenyl)(4-methoxyphenyl)iodonium trifluoroacetate (152) .215 9.21 (4-(Acetoxy)phenyl)(2-thienyl)iodonium trifluoroacetate (153) ..............216 9.22 Bis(4-(benzyoxyl)phenyl)iodonium trifluoroacetate (155) ......................217 9.23 (4-(Benzyloxy)phenyl)(3,4,5-trimethoxyphenyl)iodonium trifluoroacetate (170) .................................................................................................217 9.24 1-Methoxy-3-(2-nitrovinyl)benzene (177)417,418 .....................................218 9.25 2-(3-Methoxyphenyl)ethan-1-amine (178)417,418 ...................................218 9.26 2-(3-Methoxyphenethyl)isoindoline-1,3-dione (179) 418,419 .....................219 9.28 2-(2-(3-Methoxyphenethyl)isoindoline-1,3-dione)(4- methoxyphenyl)iodonium trifluoroacetate (181) ...................................220 9.29 2-(2-(3-Methoxyphenethyl)isoindoline-1,3-dione)(2- methoxyphenyl)iodonium trifluoroacetate (182) ...................................221 9.30 2-(3,4-dimethoxyphenethyl)isoindoline-1,3-dione (225)418 ....................221 9.31 2-(2-iodo-4,5-dimethoxyphenethyl)isoindoline-1,3-dione (227) .............222 9.32 2-(4,5-dimethoxy-2-(tributylstannyl)phenethyl)isoindoline-1,3-dione (228)176 .............................................................................................223 9.33 (4-(5-N-[2-(1,2-Dimethoxy-phenyl)ethyl]-phthalimide)(2-thienyl)iodonium trifluoroacetate (226) .........................................................................224 9.34 Methyl (S)-2-amino-3-(2-bromo-4,5- dihydroxyphenyl) propanoate (230)408 .........................................................................................................224
Load more

Recommended publications
  • Synthetic Studies Toward Aziridinomitosenes and 9-Oxo-Pyrrolo[1,2-A]Indole Mitosanes Related to the Mitomycin and FR Heterocycles
    Synthetic Studies Toward Aziridinomitosenes and 9-Oxo-pyrrolo[1,2-a]indole Mitosanes Related to the Mitomycin and FR Heterocycles by Susan D. Wiedner A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Chemistry) in The University of Michigan 2009 Doctoral Committee: Professor Edwin Vedejs, Chair Professor David Sherman Associate Professor Anna Mapp Associate Professor John Wolfe © Susan D. Wiedner 2009 To my grandfather, Francis Jerome Trick ii Acknowledgements I would first like to thank my advisor, Professor Edwin Vedejs, for advising me over the last six years. His drive for understanding chemical problems and discovering new chemistry imparted on me a desire to understand, analyze, and circumvent multiple synthetic difficulties which I encountered during my graduate work. Without his guidance and example, I would not have been successful. Furthermore, I would like to thank him for the opportunity to discover my “talents” during this incredibly challenging and rewarding research experience. I also want to thank past and present Vedejs group members. A special thanks goes to Tim, Trisha, and Drew for helping me transition into the lab during my first and second year. Thank you Jeremy and Musong for your previous work on the FK317 project. Thanks John, Aleks, Li, Dan and Eoghan for many discussions about chemistry. I especially want to thank Bob and Val for their insightful suggestions regarding my project, for reading and editing my thesis, and for their friendship. Most importantly, I would like to thank my family. My husband Eric has been by my side for most of my graduate career and I could not have gotten through this challenging process without his support and love.
    [Show full text]
  • Syntheses and Evaluation of Phthalocyanine Derivatives For
    Louisiana State University LSU Digital Commons LSU Doctoral Dissertations Graduate School 2008 Syntheses and Evaluation of Phthalocyanine Derivatives for Applications in Photodynamic and Boron Neutron Capture Therapies for Cancer Hairong Li Louisiana State University and Agricultural and Mechanical College, [email protected] Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_dissertations Part of the Chemistry Commons Recommended Citation Li, Hairong, "Syntheses and Evaluation of Phthalocyanine Derivatives for Applications in Photodynamic and Boron Neutron Capture Therapies for Cancer" (2008). LSU Doctoral Dissertations. 3294. https://digitalcommons.lsu.edu/gradschool_dissertations/3294 This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU Doctoral Dissertations by an authorized graduate school editor of LSU Digital Commons. For more information, please [email protected]. SYNTHESES AND EVALUATION OF PHTHALOCYANINE DERIVATIVES FOR APPLICATIONS IN PHOTODYNAMIC AND BORON NEUTRON CAPTURE THERAPIES FOR CANCER A Dissertation Submitted to the Graduate Faculty of the Louisiana State University and Agricultural and Mechanical College in partial fulfillment of the requirement for the degree of Doctor of Philosophy in The Department of Chemistry By Hairong Li B.S., Nankai University, 2001 M.S., Nankai University, 2004 December, 2008 DEDICATION To my parents: Mingzhen Tang and Baiwen Li. Thank you for being wonderful parents; for giving me life, unconditional love, support, education, guidance, most importantly the freedom to make my own decisions. You have always been my source of strength and inspiration. I can never thank you enough for what you have done in my life.
    [Show full text]
  • Structural Determination of Torlon 4000T Polyamide-Imide by NMR Spectroscopy Robertson, Gilles; Guiver, Michael; Yoshikawa, M.; Brownstein, Sydney
    NRC Publications Archive Archives des publications du CNRC Structural determination of Torlon 4000T polyamide-imide by NMR spectroscopy Robertson, Gilles; Guiver, Michael; Yoshikawa, M.; Brownstein, Sydney This publication could be one of several versions: author’s original, accepted manuscript or the publisher’s version. / La version de cette publication peut être l’une des suivantes : la version prépublication de l’auteur, la version acceptée du manuscrit ou la version de l’éditeur. For the publisher’s version, please access the DOI link below./ Pour consulter la version de l’éditeur, utilisez le lien DOI ci-dessous. Publisher’s version / Version de l'éditeur: https://doi.org/10.1016/j.polymer.2003.12.029 Polymer, 45, 2004 NRC Publications Record / Notice d'Archives des publications de CNRC: https://nrc-publications.canada.ca/eng/view/object/?id=06c75579-15bb-4fb1-b403-590399c28976 https://publications-cnrc.canada.ca/fra/voir/objet/?id=06c75579-15bb-4fb1-b403-590399c28976 Access and use of this website and the material on it are subject to the Terms and Conditions set forth at https://nrc-publications.canada.ca/eng/copyright READ THESE TERMS AND CONDITIONS CAREFULLY BEFORE USING THIS WEBSITE. L’accès à ce site Web et l’utilisation de son contenu sont assujettis aux conditions présentées dans le site https://publications-cnrc.canada.ca/fra/droits LISEZ CES CONDITIONS ATTENTIVEMENT AVANT D’UTILISER CE SITE WEB. Questions? Contact the NRC Publications Archive team at [email protected]. If you wish to email the authors directly, please see the first page of the publication for their contact information.
    [Show full text]
  • WO 2018/013686 Al 18 January 2018 (18.01.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2018/013686 Al 18 January 2018 (18.01.2018) W !P O PCT (51) International Patent Classification: Declarations under Rule 4.17: C07D 209/14 (2006.01) A61K 31/4045 (2006.01) — of inventorship (Rule 4.1 7(iv)) (21) International Application Number: Published: PCT/US20 17/04 1709 — with international search report (Art. (22) International Filing Date: 12 July 2017 (12.07.2017) (25) Filing Language: English (26) Publication Langi English (30) Priority Data: 62/361,3 16 12 July 2016 (12.07.2016) US (71) Applicant: CONCERT PHARMACEUTICALS, INC. [US/US]; 99 Hayden Avenue, Suite 500, Lexington, MA 02421 (US). (72) Inventor: SILVERMAN, I., Robert; 36 Orvis Road, Ar lington, MA 02474 (US). (74) Agent: ABELLEIRA, Susan, M. et al; Foley Hoag LLP, 155 Seaport Boulevard, Boston, MA 02210-2600 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Hélène LAJOUS
    THESE DE DOCTORAT DE L'UNIVERSITE D'ANGERS L'UNIVERSITE DE LIEGE COMUE UNIVERSITE BRETAGNE LOIRE ECOLE DOCTORALE N° 605 ECOLE DOCTORALE Biologie Santé Chimie moléculaire, supramoléculaire et fonctionnelle Spécialité : Technologies biomédicales, Vectorisation, Nanomédecine, Thérapie cellulaire et génique, Médecine régénératrice et Biomatériaux Par Hélène LAJOUS Cisplatine : une vieille molécule pour de nouveaux défis Développement d’une prodrogue macromoléculaire multifonctionnelle applicable au traitement local du glioblastome Thèse présentée et soutenue à Angers, le 22 mai 2018 Unités de recherche : Centre de Recherche en Cancérologie et Immunologie Nantes Angers (CRCINA), INSERM U1232 Centre d’Etude et de Recherche sur les Macromolécules (CERM) Rapporteurs avant soutenance : Pr. Karine ANDRIEUX Professeure, Université Paris Descartes Dr. Sandrine CAMMAS-MARION Chargée de recherche, CNRS, HDR, Ecole Nationale Supérieure de Chimie de Rennes Composition du Jury : Pr. Christine JEROME Professeure, Université de Liège Présidente Pr. Karine ANDRIEUX Professeure, Université Paris Descartes Dr. Sandrine CAMMAS-MARION Chargée de recherche, CNRS, HDR, Ecole Nationale Supérieure de Chimie de Rennes Dr. Elodie VAULEON MD, PhD, Centre Eugène Marquis, Service d’Oncologie Médicale, Université de Rennes Dr. Caroline ROBIC PhD, Guerbet Dr. Emmanuel GARCION Directeur de recherche, INSERM, Université d’Angers Directeur de thèse Dr. Philippe LECOMTE Chercheur, FNRS, Université de Liège Co-directeur de thèse An Seppi “One day, we imagine that cancer biology and treatment – at present, a patchwork quilt of cell biology, genetics, histopathology, biochemistry, immunology, and pharmacology – will become a science with a conceptual structure and logical coherence that rivals that of chemistry or physics.” Douglas Hanahan & Robert A. Weinberg, 2000. The hallmarks of cancer. Cell, 100, pp.
    [Show full text]
  • High-Temperature in Situ Crystallographic Observation of Reversible Gas Sorption in Impermeable Organic Cages
    High-temperature in situ crystallographic observation of reversible gas sorption in impermeable organic cages Seung Bin Baeka,1, Dohyun Moonb,1, Robert Grafc, Woo Jong Choa, Sung Woo Parkd, Tae-Ung Yoone, Seung Joo Chof, In-Chul Hwangd,2, Youn-Sang Baee, Hans W. Spiessc, Hee Cheon Leed, and Kwang S. Kima,3 aDepartment of Chemistry and Center for Superfunctional Materials, Ulsan National Institute of Science and Technology, Ulsan 689-798, Korea; bPohang Accelerator Laboratory, Pohang 790-834, Korea; cMax-Planck-Institute for Polymer Research, 55128, Mainz, Germany; dDepartment of Chemistry, Pohang University of Science and Technology, Pohang 790-784, Korea; eDepartment of Chemical and Biomolecular Engineering, Yonsei University, Seoul 120-749, Korea; and fDepartment of Cellular Molecular Medicine, College of Medicine, Chosun University, Gwangju 501-759, Korea Edited by Galen D. Stucky, University of California, Santa Barbara, CA, and approved October 7, 2015 (received for review March 6, 2015) Crystallographic observation of adsorbed gas molecules is a highly single-crystal structures have been determined at low temperatures difficult task due to their rapid motion. Here, we report the in (16, 28–36). situ single-crystal and synchrotron powder X-ray observations of If the permanent channels large enough for the guest diffusion reversible CO2 sorption processes in an apparently nonporous or- between voids are not present, such a material is nonporous and ganic crystal under varying pressures at high temperatures. The impermeable to the guest molecules even if there are cages host material is formed by hydrogen bond network between 1,3,5- available for the guest storage. If transient pathways between tris-(4-carboxyphenyl)benzene (H3BTB) and N,N-dimethylformamide voids can be made with molecular gates in special conditions, the (DMF) and by π–π stacking between the H3BTB moieties.
    [Show full text]
  • Relevance of N-Nitroso Compounds to Human Cancer: Exposures and Mechanisms
    WORLD HEALTH ORGANIZATION ' Ю INTERNATIONAL AGENCY FOR RESEARCH ON CANCER RELEVANCE OF N-NITROSO COMPOUNDS TO HUMAN CANCER: EXPOSURES AND MECHANISMS Proceedings of the IXth International Symposium on N-Nitroso Compounds, held in Baden, Austria, 1-5 SeptemЬеr 1986 Co-sponsored by: National Cancer Institute (USA) Dr M. Okada Giapan) and associated Japanese industrial sponsors Thermedics Inc. (USA) Ciba-Geigy (Switzerland) Imperial Chemical Industries (UK) EDITORS H. BARTSCH, T.K. 0 NЕILL & R. SCHULTE-HERMANN JAR SCIENTIFIC PUBLICATIONS NO. 84 INTERNATIONAL AGENCY FOR RESEARCH ON CANCER LYON 1987 CONTENTS Foreword.................................................................. 1 Introduction................................................................ 3 Overview................................................................... 5 Keynote address P.N. Magee ............................................................. 11 1. MOLECULAR AND BIOCHEMICAL MECHANISMS Biochemical events in nitrosamine-induced hepatocarcinogenesis: relevance of animal data to human carcinogenesis R.Schulte-Hermann .....................................................17 Biochemical and molecular effects of N-nitroso compounds in human cultured cells: an overview C.C. Harris .............................................................20 Activation of the human c-Ha-ras-1 proto-oncogene by in-vitro reaction with N-nitroso- methyl(acetoxymethyl)amine S. Hirani-Hojatti, J.R. Milligan & M.C. Archer ..............................26 Specificity of OЬ-alkylguanine-DNA
    [Show full text]
  • Exploring the Lewis Acid Assisted 19F/18F-Isotopic Exchange Radiochemistry of BODIPY Dyes, and Dipods: Development of A
    Expanding the Toolbox: Exploring the Lewis Acid Assisted 19F/18F-Isotopic Exchange Radiochemistry of BODIPY Dyes, and DiPODS: Development of a Novel Bioconjugation Reagent. A Thesis Submitted to the College of Graduate & Postdoctoral Studies In Partial Fulfillment of the Requirements For the Degree of Master of Science In the Department of Chemistry University of Saskatchewan Saskatoon By Whitney Shannon © Copyright Whitney Shannon, March 1st, 2021. All rights reserved. Unless otherwise noted, copyright of the material in this thesis belongs to the author. Permission to Use In presenting this thesis in partial fulfillment of the requirements for a graduate degree from the University of Saskatchewan, I agree that the Libraries of this University may make it freely available for inspection. I further agree that permission for copying of this thesis in any manner, in whole or in part, for scholarly purposes may be granted by the professors who supervised this thesis work or, in their absences, by the Head of the Department or the Dean of the College in which my thesis work was done. It is understood that any copying or publication or use of this thesis or parts thereof for financial gain shall not be allowed without my written permission. It is also understood that due recognition shall be given to me and to the University of Saskatchewan in any scholarly use which may be made of any material in my thesis. Requests for permission to copy or to make other use of material in this thesis in whole or in part should be addressed to: Head of the Department of Chemistry Dean of College of Graduate & Postdoctoral Studies 170 Thorvaldson Building, 110 Science Place 116 Thorvaldson Building, 110 Science Place University of Saskatchewan University of Saskatchewan Saskatoon, Saskatchewan S7N 5C9 Saskatoon, Saskatchewan S7N 5C9 Canada Canada i Abstract Radiochemical diagnostics and therapeutics benefit from pairing with a compliment second imaging modality.
    [Show full text]
  • Determination of Hydroxyl Groups in Biorefinery Resources Via
    PROTOCOL https://doi.org/10.1038/s41596-019-0191-1 Determination of hydroxyl groups in biorefinery resources via quantitative 31P NMR spectroscopy Xianzhi Meng 1, Claudia Crestini 2*, Haoxi Ben3, Naijia Hao1, Yunqiao Pu 4, Arthur J. Ragauskas 1,4,5* and Dimitris S. Argyropoulos 6* The analysis of chemical structural characteristics of biorefinery product streams (such as lignin and tannin) has advanced substantially over the past decade, with traditional wet-chemical techniques being replaced or supplemented by NMR methodologies. Quantitative 31P NMR spectroscopy is a promising technique for the analysis of hydroxyl groups because of its unique characterization capability and broad potential applicability across the biorefinery research community. This protocol describes procedures for (i) the preparation/solubilization of lignin and tannin, (ii) the phosphitylation of their hydroxyl groups, (iii) NMR acquisition details, and (iv) the ensuing data analyses and means to precisely calculate the content of the different types of hydroxyl groups. Compared with traditional wet-chemical techniques, the technique of quantitative 31P NMR spectroscopy offers unique advantages in measuring hydroxyl groups in a single spectrum with high signal resolution. The method provides complete quantitative information about the hydroxyl groups with small amounts of sample (~30 mg) within a relatively short experimental time (~30–120 min). 1234567890():,; 1234567890():,; Introduction Over the past decade, advances in genetic engineering and biotechnology have led to a new manu- facturing concept directed at converting renewable lignocellulosics to valuable fuels and products, generally referred to as the biorefinery1. The development of biomass-based biorefineries, in turn, has been the main impetus for developing methods to assess the characteristics of the biorefinery feedstocks, process intermediates, and final products.
    [Show full text]
  • The Development of Water-Soluble Olefin Metathesis Catalysts
    49 CHAPTER 3 Initial Efforts to Develop a Small-Molecule Water-Soluble Olefin Metathesis Catalyst Containing an N-Heterocyclic Carbene Ligand 50 Abstract Early research pursuing a discrete, water-soluble olefin metathesis catalyst containing an N-heterocyclic carbene (NHC) ligand is reported. Two general strategies for generating the desired catalyst are outlined. The first strategy incorporates water-soluble groups into the NHC ligand. The second strategy incorporates water-soluble groups onto phosphine, pyridine, and isopropoxybenzylidene ligands, which are ligands that dissociate during metathesis reactions. The syntheses of ligands and ruthenium complexes inspired by these two strategies are described. 51 Introduction Earlier chapters describe the development and utility of catalysts 1–8 and their impact on olefin metathesis.1-14 Of particular interest to this chapter are catalysts 6–8, which are soluble and operate in polar protic solvents, including water.9-14 The first homogenous, well-defined water-soluble catalysts, complexes 6 and 7, are capable of performing ring-opening metathesis polymerization (ROMP) in water and show limited ring-closing metathesis activity in polar protic solvents.9-13 The development of catalyst 8 52 is described in Chapter 2. This catalyst also shows metathesis activity in polar protic solvents.14 The increased stability and activity of N-heterocyclic carbene (NHC)-containing olefin metathesis catalysts over their bis(phosphine) analogs inspires the production of water-soluble catalysts like 8.15-17 The hypothesis is that the benefits that NHC ligands impart on ruthenium-based olefin metathesis catalysts used in aprotic solvents will also be observed in their water-soluble analogs. Consistent with this hypothesis, catalyst 8 does show increased ROMP activity in water over the water-soluble bis(phosphine) catalyst 7.14 However, as described in Chapter 2, complex 8 is unable to mediate the metathesis of acyclic substrates in water and is less active than parent catalyst 3 in aprotic solvents.
    [Show full text]
  • “Activation of Arene-Heteroatom Bonds by Photoredox Catalysis with Visible Light”
    “Activation of arene-heteroatom bonds by photoredox catalysis with visible light” Dissertation zur Erlangung des Doktorgrades der Naturwissenschaften Dr. rer. nat. an der Fakultät für Chemie und Pharmazie der Universität Regensburg vorgelegt von Michal Májek aus Bratislava (Slowakische Republik) Regensburg 2015 The experimental part of this work was carried out between September 2012 and September 2015 at the University of Regensburg, Institute of Organic Chemistry under the supervision of Prof. Dr. Axel Jacobi von Wangelin. The thesis was submitted on: 6.11.2015 Date of the defense: 10.12.2015 Board of examiners: Prof. Dr. Olga García Mancheño (chairman) Prof. Dr. Axel Jacobi von Wangelin (1st referee) Prof. Dr. Burkhard König (2nd referee) Prof. Dr. Frank-Michael Matysik (examiner) Hey, now, baby, I’m beginning to see the light Wine in the morning and some breakfast at night Well, I’m beginning to see the light… Velvet Underground: Beginning to see the light (1968) Table of Contents: 1: Introduction 1.1 Chemistry and light 11 1.2 Chemical photocatalysis: Introduction 16 1.2.1 Chemical photocatalysis: Sensitizers 17 1.2.2 Chemical photocatalysis: Redox catalysis 19 1.2.3 Chemical photocatalysis: Scope of photoredox catalysis 25 1.3 Conclusions and outlook 32 1.4 Thesis scope 32 1.5 References 34 2: Organocatalytic visible light mediated synthesis of aryl sulfides 2.1 Introduction 41 2.2 Results and discussion 43 2.3 Conclusion 46 2.4 Experimental part 46 2.5 References 59 3: On the mechanism of photocatalytic reactions with eosin Y 3.1
    [Show full text]
  • Structure and Ordering in Solvents and Solutions of Carbon Nanotubes
    Structure and Ordering in Solvents and Solutions of Carbon Nanotubes Nadir S. Basma A thesis submitted in partial fulfilment of the requirements for the degree of Doctor of Philosophy Department of Physics and Astronomy University College London October 2018 Dedicated to my parents ii Declaration I, Nadir Basma, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated, and that appropriate credit has been given where reference has been made to the work of others. Copyright © 2018 by Nadir S. Basma “The copyright of this thesis rests with the author. No quotations from it should be published without the author’s prior written consent and information derived from it should be acknowledged.” iii Abstract Our lack of understanding of interactions between nanoparticles in liquids is impeding our ability to controllably produce and manipulate nanomaterials. Traditionally, nanoparticle dispersions are treated using classical colloidal theories originally developed for micron-scale particles. These theories have recently been called into question as significant deviations from micro-scale models are routinely seen as dimensions of the dispersed particle are reduced. The deviations are prominent in the liquid phase where low-dimensional nanomaterials are often processed to produce individualised species with which desirable properties are associated. In this context, a few solvents have proven to more effective than others. Yet, their liquid structures, which ultimately underpins their solvation properties, has not been established. In the first part of this work, advanced neutron scattering methods was used to probe the structure of three solvents: N-methyl-2-pyrrolidone (NMP), dimethylformamide (DMF) and dimethylacetamide (DMA).
    [Show full text]